VEGFA and renal cell adenocarcinoma: In the early 1990s, a better understanding of RCC biology led to targeting angiogenesis, using antiangiogenic agents, including anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinases (sunitinib, sorafenib) and anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab.